Clinical Trial Update: Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating Salovum™ and SPC-Flakes™ to mitigate abemaciclib-induced gastrointestinal toxicity in early breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• SPC Flakes
• Salovum

Snippet

Sponsor: Henrik Lindman | Conditions: Early-stage Breast Cancer, Diarrhea | Phase 3 | Status: UNKNOWN